Glucose Metabolism Clinical Trial
— LoPoCardioOfficial title:
Long-term Effects of a Potato-based Food Pattern vs a Rice / Pasta-based Food Pattern on Fasting & Postprandial Cardiometabolic Health; The LoPoCardio - Trial
NCT number | NCT04851041 |
Other study ID # | METC19-067 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 3, 2021 |
Est. completion date | May 1, 2024 |
The researchers investigate the effect of long-term (12-weeks) consumption of diets rich in boiled potatoes versus those rich in rice or pasta on established cardiovascular risk parameters. These carbohydrate sources will be part of a recommended healthy dietary pattern to mimic as closely as possible current dietary guidelines, facilitating the implementation of the outcomes.
Status | Recruiting |
Enrollment | 56 |
Est. completion date | May 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: - The inclusion criteria are: - Aged between 40-70 years - Men and women - 18-70 years - BMI between 25-35 kg/m2 (overweight and obese) - Serum total cholesterol < 8.0 mmol/L (further testing is recommended for excessive hyperlipidemia [serum total cholesterol = 8.0 mmol/L] according to the Standard for cardiovascular risk management of the Dutch general practitioners community [NHG]) - Serum triacylglycerol < 4.5 mmol/L - No current smoker - No diabetic patients - No familial hypercholesterolemia - No abuse of drugs - Not more than 4 alcoholic consumption per day with a maximum of 21 per week?? - Stable body weight (weight gain or loss < 3 kg in the past three months) - No use of medication known to treat blood pressure, lipid or glucose metabolism - No use of an investigational product within another biomedical intervention trial within the previous 1-month - No severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - No active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident - Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study - No difficult venipuncture as evidenced during the screening visit - Willing to comply to study protocol during study - Informed consent signed Exclusion Criteria: - The exclusion criteria are: - Allergy or intolerance to potatoes, pasta or rice - Serum total cholesterol = 8.0 mmol/L - Serum triacylglycerol = 4.5 mmol/L - Current smoker, or smoking cessation <12 months - Diabetic patients - Familial hypercholesterolemia - Abuse of drugs - More than 4 alcoholic consumptions per day or 21 per week - Unstable body weight (weight gain or loss > 3 kg in the past three months) - Use medication known to treat blood pressure, lipid or glucose metabolism - Use of an investigational product within another biomedical intervention trial within the previous 1-month - Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident - Not willing to give up being a blood donor from 8 weeks before the start of the study, during the study or for 4 weeks after completion of the study - Not or difficult to venipuncture as evidenced during the screening visit - Use of over-the-counter and prescribed medication or supplements, which may interfere with study measurements to be judged by the principal investigator; - Use of oral antibiotics in 40 days or less prior to the start of the study; - Blood donation in the past 3 months before the start of the study - Not willing to comply to study protocol during study or sign informed consent |
Country | Name | City | State |
---|---|---|---|
Netherlands | Metabolic Research Unit Maastricht | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Netherlands,
Camire ME, Kubow S, Donnelly DJ. Potatoes and human health. Crit Rev Food Sci Nutr. 2009 Nov;49(10):823-40. doi: 10.1080/10408390903041996. Review. — View Citation
Jacome-Sosa M, Parks EJ, Bruno RS, Tasali E, Lewis GF, Schneeman BO, Rains TM. Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions. Adv Nutr. 2016 Mar 15;7(2):364-74. doi: 10.3945/an.115.010397. Print 2016 Mar. Review. — View Citation
King JC, Slavin JL. White potatoes, human health, and dietary guidance. Adv Nutr. 2013 May 1;4(3):393S-401S. doi: 10.3945/an.112.003525. Review. — View Citation
Robertson TM, Alzaabi AZ, Robertson MD, Fielding BA. Starchy Carbohydrates in a Healthy Diet: The Role of the Humble Potato. Nutrients. 2018 Nov 14;10(11). pii: E1764. doi: 10.3390/nu10111764. Review. — View Citation
Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, Folsom AR, Rimm EB, Willett WC, Solomon SD. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. 2018 Sep;3(9):e419-e428. doi: 10.1016/S2468-2667(18)30135-X. Epub 2018 Aug 17. — View Citation
Shan Z, Rehm CD, Rogers G, Ruan M, Wang DD, Hu FB, Mozaffarian D, Zhang FF, Bhupathiraju SN. Trends in Dietary Carbohydrate, Protein, and Fat Intake and Diet Quality Among US Adults, 1999-2016. JAMA. 2019 Sep 24;322(12):1178-1187. doi: 10.1001/jama.2019.13771. — View Citation
Simpson SJ, Le Couteur DG, James DE, George J, Gunton JE, Solon-Biet SM, Raubenheimer D. The Geometric Framework for Nutrition as a tool in precision medicine. Nutr Healthy Aging. 2017 Dec 7;4(3):217-226. doi: 10.3233/NHA-170027. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory objective endothelial (dys)function markers | Measured by sE-selectin, sICAM, sVCAM, and MCP-1 in al visits
To investigate if potato consumption by overweight and obese (BMI25-35 kg/m2) men and women changes: Endothelial (dys)function markers (sE-selectin, sICAM, sVCAM, and MCP-1) - Liver enzymes (e.g. ALAT, ASAT, gGT, bilirubin) Calculated insulin secretory function (HOMA%B index) Micro-albumineria and kidney function (estimated GFR) Plasma incretins / satiety hormones (PYY, GLP, Ghrelin) |
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Other | Exploratory objective liver enzymes | Measured by liver enzymes (ALAT, ASAT, gGT, bilirubin) | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Other | Exploratory objective calculated insulin secretory function | Measured by HOMA%B index | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Other | Exploratory objective micro-albumineria and kidney function | Measured by estimated GFR | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Other | Exploratory objective plasma incretins / satiety hormones in fasting and postprandial conditions | Following a high-fat, high-carb meal, measured by PYY, GLP, ghrelin. | 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7) | |
Primary | Chronic glucose metabolism | Measured by change in average daily glucose concentrations over a 15 hours period between waking up and going to bed 7:00AM - 22:00PM for three days, which is calculated based on the total area under the curve (tAUC) using a continuos glucose monitor. | pre- intervention and post- intervention (12 weeks) | |
Secondary | Lipid metabolism | Measured by fasting serum C-peptide, lipids and lipoproteins in all visits | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Secondary | Glucose metabolism | Measured by fasting plasma glucose, insulin, and calculated HOMA- IR in all visits | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Secondary | Low grade inflammation | Measured by inflammation plasma markers (hsCPR, IL6, IL8, TNFa) | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Secondary | Postprandial glucose metabolism | Following a high-fat, high-carb meal, measured by plasma glucose, insulin. | 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7) | |
Secondary | Postprandial TAG metabolism | Following a high-fat, high-carb meal, measured by plasma TAG. | 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7) | |
Secondary | 24h urine samples micronutrient profiles | Measured by 24 urine collection. | 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7) | |
Secondary | Quality of life questionnaire | Assessed with a 32-item questionnaire (including social, spiritual, emotional, cognitive, physical, activities of daily living, and integrated quality of life) | 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7) | |
Secondary | Mood, degree of pleasantness and arousal | Assessed with the Affect grid | 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7) | |
Secondary | Fatigue | Assessed using the FSS, a 9-item questionnaire that is used to determine the severity of fatigue a subject experienced in the past week during daily activities | 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7) | |
Secondary | Cognitive performance | Assessed with a validated neuropsychological test battery (CANTAB) | 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7) | |
Secondary | Venular and arteriolar diameters | Assessed via fundus photography | 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7) | |
Secondary | Office blood pressure | Measured by office blood pressure monitor in all visits | 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7) | |
Secondary | 36h blood pressure profiles | Assessed via wearables blood pressure monitor | 12 weeks intervention: Pre- intervention (visit-1) and post- intervention (visit 6) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04120051 -
The SIMBA Project - The Effect of a Prebiotic Supplement on Glucose Metabolism and Gut Microbiota in Obese Adults
|
N/A | |
Completed |
NCT01686815 -
Cross-Sectional Iloperidone IVGTT
|
||
Completed |
NCT01034293 -
Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning
|
N/A | |
Completed |
NCT05642052 -
Feasibility Study of a Community Pilot Project for the Prevention of Alzheimer's Disease: the KetoHome Study.
|
N/A | |
Completed |
NCT03851744 -
High Altitude and Exogenous Carbohydrate Oxidation
|
N/A | |
Completed |
NCT05801731 -
A Decentralized Study on Dietary Influences on Cognitive Functions
|
N/A | |
Completed |
NCT04611945 -
Westlake Sailing Cohort
|
||
Active, not recruiting |
NCT04737694 -
Ketone Supplements and Substrate Oxidation and Physical Performance
|
N/A | |
Completed |
NCT05282641 -
Effects of 10-gram Collagen Protein Hydrolysate on Cardiometabolic Health
|
N/A | |
Completed |
NCT03648112 -
Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety
|
N/A | |
Completed |
NCT05313594 -
Digital Twin - Modelling Postprandial Triglyceride and Glucose Responses
|
||
Active, not recruiting |
NCT01390688 -
Brain-derived Neurotrophic Factor and Cogntive Function
|
N/A | |
Recruiting |
NCT00953966 -
Metabolic Changes Induced by Genetically Modified Potatoes
|
N/A | |
Completed |
NCT04928872 -
Macronutrient Distribution and Plasma Metabolites to Model Meals Composition
|
||
Completed |
NCT02854709 -
Effects of Sleep Extension on Glucose Metabolism in Chronically Sleep Deprived Individuals
|
N/A | |
Completed |
NCT00227500 -
Pravastatin for Hyperlipidaemia in HIV.
|
Phase 4 | |
Recruiting |
NCT04894526 -
Alternating Energy Intake and Blood Fat Content After a Meal
|
N/A | |
Recruiting |
NCT04971408 -
Impact of Passive Heat on Metabolic, Inflammatory and Vascular Health in Persons With Spinal Cord Injury
|
N/A | |
Terminated |
NCT04234009 -
Lifestyle and Brain Vascular Function
|
N/A | |
Completed |
NCT01877460 -
Sodium Alginate in Chocolate Milk, Satiety and Glycemic Control
|
N/A |